MOLE CULAR ANALYSIS FOR PRECISION ONCOLOGY

Assays - Challenges in analysis, reporting and interpretation of results - Integration in Clinical Practice

School of Medicine University of Crete

23-24th February



WHO WE ARE





Dimitrios Mavroudis

Professor of Medical Oncology Department of Medical Oncology University General Hospital of Heraklion Laboratory of Translational Oncology, School of Medicine, University of Crete

Sofia Agelaki

Professor of Medical Oncology Department of Medical Oncology University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete

John Souglakos

Professor of Medical Oncology Department of Medical Oncology University General Hospital of Heraklion Laboratory of Translational Oncology, School of Medicine, University of Crete

Post-doctoral Researchers Kleita Michaelidou, MSc, PhD Maria A Papadaki, PhD Eleni Politaki, MSc, PhD Maria Sfakianaki. PhD

Research Assistant
Despoina Aggouraki, MSc

Technicians Georgia Saloustrou

PhD students Chara Koutoulaki, BSc Konstantinos Vogiatzoglou, MSc

MSc students Anna Stylianou

Undergraduate Ilias Boronikolas Sofia Chatziavraam Vasileios Vagiatis Sofia Gounaki

Dear Colleagues,

As we stand at the forefront of a transformative era in oncology, molecular diagnostics holds a key role in cancer diagnosis, risk assessment and treatment tailoring, thus empowering precision in cancer management.



The two-day masterclass entitled Molecular Analysis for Precision Oncology, organized by the Laboratory of Translational Oncology in collaboration with the Department of Medical Oncology of the University General Hospital of Heraklion, brings together distinguished experts in the field of Molecular Diagnostics and Medical Oncology aiming to bridge the gap in the understanding of the challenges associated with biomarker analysis and integration into clinical decision making.

Sessions are tailored to provide young oncologists with insights into key cancer genetics concepts and tumor profiling approaches, cutting-edge methods in biomarker testing and clinical applications, to cover existing gaps in navigating and interpreting reports and to highlight the pivotal role of biomarkers in tailoring individualized treatment strategies for cancer patients.

After attendance participants are anticipated:

- ✓ To get an inside look at tumor sequencing approaches
- √ To understand the opportunities and challenges of biomarker analysis and reporting
- To understand current paradigms of molecularly guided therapy options
- √ To integrate this knowledge into clinical decision making within molecular tumor boards

However, this workshop is not just about learning; it is an opportunity to have a hands-on experience in the Lab, to engage in knowledgeprovoking discussions with experts, share experiences, and build collaborative networks.

Wishing you an informative and inspiring experience!

Prof. Sofia Agelaki Prof. Dimitrios Mavroudis The Laboratory of Translational Oncology, has been established at the Faculty of Medicine, University of Crete (UoC) and operates in close collaboration with the Department of Medical Oncology, University General Hospital of Heraklion to bridge translational and clinical research activities.

The Department of Medical Oncology (DMO) is the reference center for patients with cancer for the area of Crete, Greece, since it receives approximately 1.000 new cancer patients per year and follows more than 10.000 cancer patients. The mission of the DMO is to provide clinical care to patients with cancer, to perform basic and clinical research, and to provide education and training to the next generation of scientists who are focused on the biology and treatment of cancer.

In the Laboratory of Translational Oncology (LTO) clinical and translational researchers and clinical oncologists interact, collaborate, and pool their expertise towards advancing cancer care and research. The Laboratory has all the equipment needed for its research activities aiming for a better understanding of the molecular mechanisms underlying cancer development and progression and for the development of novel issue and liquid biopsy-based prognostic and predictive biomarkers to advance precision medicine in Oncology.

LTO is part of the Hellenic Molecular Oncology Network (EDIMO), with the aim to enhance the prevention, diagnosis, and treatment of cancer patients and to develop new techniques for personalizing health care services offered to cancer patients.

LTO has actively participated in several EU-funded projects, as well as in National funded research projects.



ENERAL INFORMATION

Workshop Venue

School of Medicine, University of Crete Auditorium of Postgraduate Studies, Wing 7A




This rst workshop, organised by Anticancer Research Support Association (ARSA)

on 23-24 February 2024

TARGET AUDIENCE

Oncology Fellows/Residents
Researchers and others involved in the care of cancer patients.





CME Accreditation

This course has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®s).



PARTICIPANT

Agelaki Sofia	Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete
Aggouraki Despoina	Research Assistant, Laboratory of Translational Oncology, School of Medicine, University of Crete
Androulakis Nikolaos	Head Department of Medical Oncology, General Hospital of Heraklion "Venizeleio and Pananio"
Bompolaki Iliada	Medical Oncologist, General Hospital of Chania "Agios Georgios"
Boukouris Aristeidis	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
Bozionelou Vassiliki	Medical Oncologist, University General Hospital of Heraklion
Chatzaki Ekaterini	Professor of Pharmacology, Laboratory of Pharmacology, Faculty of Medicine, Democritus University, Greece
Dimaras Pantelis	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
Drositis Ioannis	Visiting Professor, Medical Oncologist, General Hospital of Heraklion "Venizeleio and Pananio"
Ferfadis Evaggelos	Medical Oncologist, Metaxa Cancer Hospital - Department of Medical Oncology
Fotsitzoudis Charal.	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
Georgiadou Maria	Medical Oncologist, University General Hospital of Heraklion
Joosse Simon	Assoc. Professor, Head of research group, Department of Tumor Biology, University Medical Center Hamburg-Eppendorf, Germany
Kalbakis Konst.	Medical Oncologist, University General Hospital of Heraklion
Kalykaki Antonia	Medical Oncologist, University General Hospital of Heraklion
Kamaratou Maria	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
Karachaliou Niki	Medical Director, Global Clinical Development, Merck KGaA, Darmstadt, Germany
Keklikoglou loanna	Assistant Professor, Department of Biology, University of Crete
Kontopodis Emm.	Medical Oncologist, General Hospital of Heraklion "Venizeleio and Pananio"
Koutoulaki Chara	PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete
Koutsopoulos Anast.	Professor of Pathology, School of Medicine, University of Crete
Kyriakidou Athina	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion
Linardaki Emman.	PhD, FORTH-IMBB Diagnostic Genetics and Precision Medicine (DIGENIA)
Linardopoulos Spiros	Director, Translational Science, Oncology, AstraZeneca
Liontos Michail	Assistant Professor, Department of Clinical Therapeutics, National and Kapodistrian University of Athens
Lydaki Danae	Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion

Mala Anastasia Medical Oncologist, University General Hospital of Heraklion Manolakou Stavroula Medical Oncologist, cooperator IASIS General Clinic (Chania), outpatient office in Chania and Rethymno, Crete **Mavroudis Dimitrios** Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete Michaelidou Kleita Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete Papadaki Maria Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete Papageorgiou Foteini Diagnostics Lead Oncology, AstraZeneca, Greece Politaki Eleni Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete Rovithi Maria Medical Oncologist, General Hospital of Agios Nikolaos, Crete Saetta Angeliki Professor, First Department of Pathology, Medical School, National and Kapodistrian University of Athens Saloustros Emman. Associate Professor, General University Hospital of Larissa Saloustrou Georgia Technician, Laboratory of Translational Oncology, School of Medicine, University of Crete Sfakianaki Maria Post-doctoral Researcher, Laboratory of Translational Oncology, School of Medicine, University of Crete Siametis Athanasios Post-doctoral Researcher, Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology–Hellas Souglakos Ioannis Professor of Medical Oncology, Department of Medical Oncology, University General Hospital of Heraklion, Laboratory of Translational Oncology, School of Medicine, University of Crete **Stoupis Ioannis** Medical Oncologist, General Hospital of Heraklion "Venizeleio and Pananio" Svoliantopoulos Konst. Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion Tsaknakis Grigoris Post-doctoral Researcher, Haemopoiesis Research Laboratory, School of Medicine, University of Crete Vamvakas Lambros Medical Oncologist, University General Hospital of Heraklion Vardakis Nikolaos Medical Oncologist, University General Hospital of Heraklion Vasilakopoulou Maria Assistant Professor, School of Medicine, University of Crete Vogiatzoglou Konst. PhD student, Laboratory of Translational Oncology, School of Medicine, University of Crete Zairi Eleni Medical Oncologist, St Luke's Hospital Thessaloniki Greece Zarkavelis George Medical Oncologist, Medical Oncology Clinic -University Hospital of Ioannina Zioudas Chrysostomos Oncology Resident, Department of Medical Oncology, University General Hospital of Heraklion Zoumpourlis Vassilis Research Professor, Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation, Athens

Tumor Sequencin

Cancer Genomics and Tumor Sequencing

09:00 Meeting at University of Crete, School of Medicine

09:00 - 10:30 The genetics of cancer

J. Souglakos, D. Mavroudis

09:00 - 09:20 • The hallmarks of cancer I. Keklikoglou

09:20 - 10:00 • Historical retrospection in the research of the genetic basis

of cancer V. Zoumpourlis

10:00 - 10:20 • Molecular alterations in cancer **K. Michaelidou**

10:20 - 10:30 • Q and A

10:30 - 12:30 Sequencing Methods for the Identification of Targetable Molecular Alterations in Cancer

A. Saetta, J. Souglakos

10:30 - 10:50 • NGS terminology G. Tsaknakis

10:50 - 11:20 • Available platforms and sequencing chemistry A. Saetta

• Analysis of sequencing results: Biological and clinical

classification of genetic variants A. Saetta

• Quality assessment of NGS testing **F. Papageorgiou**

12:10 - 12:30 • Q and A

12:30 - 13:00 Coffee Break

Friday 🗖



13:00 - 14:30 Tumor Sequencing in the clinic

E. Linardaki, N Androulakis

- The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) M. Georgiadou
- Update on the recommendations on the use of NGS for patients with metastatic cancer **M. Rovithi**
- 13:45 14:05 The NGS report: minimal content requirements **E. Linardaki**
- 14:05 14:20 How to read genomics reports for clinical practice? **A. Saetta**
- 14:20 14:30 Q and A

14:30 - 15:30 Lunch break

- 15:30 16:00 **D. Mavroudis, A. Saetta**
- Biomarkers for Breast Cancer: epigenetic classifiers implemented
 - in Liquid Biopsy E. Chatzaki
- 15:50 16:00 Q and A

16:00 - 17:30 Liquid Biopsy for Precision Oncology: Circulating Tumor DNA

E. Chatzaki, S. Agelaki

- Detection and Analysis of Circulating Tumor DNA (ctDNA):
 Challenges and Pitfalls S. Joosse
 - 20. 17.00 Deporting molecular results from of DNA testing
- 16:30 17:00 Reporting molecular results from cfDNA testing **S. Joosse**
- Recommendations on the use of ctDNA analysis in clinical decision making **S. Agelaki**
- 17:20 17:30 Q and A

17:30 - 18:30 Liquid Biopsy for Precision Oncology:

Circulating Tumor Cells (CTCs) E. Chatzaki, S. Joosse

- 17:30 17:55 Detection and characterization of CTCs M. Papadaki
- 17:55 18:20 Clinical utility of CTC analysis M. Papadaki
- 18:20 18:30 Q and A

18:30 - 20:30 CTC isolation and phenotypic analysis in the laboratory

M. Papadaki, E. Politaki

Trainers: D. Aggouraki, C. Koutoulaki, K. Michaelidou, M. Papadaki, E. Politaki, M. Sfakianaki, K. Vogiatzoglou

Precision Oncology - Therapeutic Targets

09:00 – 10:00 Rare EGFR mutations – HER2 mutations

N. Vardakis, G. Zarkavelis, E. Fergadis

09:00 - 09:15 • Testing (Assays, Techniques and Challenges) **K. Michaelidou**

09:15 - 09:35 • Clinical Efficacy of Approved Targeted Agents: Indications,

Efficacy and Toxicity A. Boukouris

09:35 - 09:55 • An interesting Clinical Case **K. Svoliantopoulos**

09:55 - 10:00 • Q and A

10:00 - 11:00 **MET**

M. Rovithi, V. Bozionelou

• Testing (Assays, Techniques and Challenges) N. Karachaliou

• Clinical Efficacy of Approved Targeted Agents: Indications, Efficacy and Toxicity **E. Zairi**

10:40 - 10:50 • An interesting Clinical Case E. Zairi

10:50 - 11:00 • Q and A

11:00 – 12:00 **Gene fusions: RET, ROS, ALK**

L. Vamvakas, A. Koutsopoulos

11:00 - 11:20 • Testing (Assays, Techniques and Challenges) A. Saetta

• Clinical Efficacy of Approved Targeted Agents: Indications, Efficacy and Toxicity **J. Stoupis**

11:40 - 11:50 • An interesting Clinical Case **M. Kamaratou**

11:50 - 12:00 • Q and A

12:00 – 12:30 **Coffee Break**

Saturday



12:30 – 14:00	Targeting homologous recombination deficiency in cancer E. Saloustros, M. Liontos
12:30 -12:50	 Mechanisms of DNA Damage Repair (DDR) S. Siametis
12:50 -13:30	 Homologous recombination deficiency: Concept, Assays and targeting S. Linardopoulos
13:30 -13:50 13:50 -14:00	 Current status of PARP inhibitors in the clinic M. Liontos Q and A
14:00 – 14:30 14:00 -14:20	 I. Bobolaki, K. Kalbakis Molecular testing in the treatment of patients with breast cancer A. Mala
14:20 -14:30	• Q and A

14:30 - 15:30 Lunch break

15.30 - 16:30	Rare targets: A. Kalykaki, I. Drositis, M. Vasilakopoulou
15:30 -15:55	• FGFR, IDH, NRTK: Testing and clinical efficacy of approved agents
	E. Kontopodis
15:55 -16:10	BRAF Non-V600: an interesting clinical case D. Lydaki
16:10 -16:25	FGFR2: an interesting clinical case A. Kyriakidou
16:25 -16:30	• Q and A

16.30 - 17:30 Molecular tumor boards: current and future considerations for precision oncology

G. Zarkavelis, S. Manolakou

16:30 -17:00	•	The molecular biologist's perspective A. Saetta
17:00 -17:30	•	The medical oncologist's perspective G. Zarkavelis

17.30 - 18:00 Oncology training and Precision Oncology: the trainees' perspective

E. Saloustros, M. Liontos

Ch. Zioudas, K. C. Fotsitzoudis, P. Dimaras

Open discussion with participants

18:00 – 20:30 **Tumor molecular Analysis workflow**

K. Michaelidou, M. Papadaki

18.00 - 18:30 18:00 -18:15 18:15 -18:30	
18.30 - 19:30 18:30 -18:50 18:50 -19:10 19:10 -19:30	NGS workflow: Ch. Koutoulaki, K. MichaelidouLibrary preparationSequencingData analysis

19.30 - 20:30 PCR based Analysis: A. Boukouris, P. Dimaras

Detection of KRAS and ESR1 mutations using the ddPCR

Anticancer Research Support Association (ARSA)

INFO: https://oncopog.com CONTACT: protypoevents@gmail.com